Boehringer Ingelheim‘s Social Engagement Fund has invested in Kasha Global, a startup that combines online and offline distribution to bring pharmaceuticals and health products to low-income communities across Africa. The investment supports Kasha’s mission to improve last-mile access to healthcare with a strong focus on women’s health and education.
Kasha Global operates a distribution model designed to reach underserved populations where 52% of Africans lack access to necessary healthcare. The company addresses critical gaps in healthcare delivery through its customer-centered approach emphasizing access, choice, and trust.
“Kasha is excited to partner with Boehringer in our shared mission of realizing last mile access to health products for the mass market,” said Joanna Bichsel, Founder and CEO of Kasha Global. “With Boehringer’s expertise in creating innovative healthcare solutions, and Kasha’s focus on customer-centered access, choice and trust, I look forward to a long-term partnership that wins at all levels.”
The investment is part of Boehringer’s commitment to improve the lives of 50 million people by 2030 through partnerships with social entrepreneurs addressing healthcare challenges. The pharmaceutical company’s Social Engagement Fund focuses on scaling high-impact startups that create sustainable solutions for local communities.
Kasha’s model tackles the significant challenge of substandard medicines in Africa, where up to 22.6% of medicines are fake or substandard, contributing to an estimated 500,000 annual deaths in sub-Saharan Africa. By ensuring quality pharmaceutical distribution to last-mile communities, Kasha helps address both access and safety concerns.
